Ciaran Kelly, MD
Gastroenterology · Boston, MANPI 1851406813
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,401 of the $61,658 with a category attached, or 73.6%. 9 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 31.1% of the total. Reporting peaked in 2021 at $18,159 and has fallen 83.2% since, to $3,046 in 2025. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $1503.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$19K
- GSK$9K
- Sanofi Pasteur Inc.$8K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Pfizer$7K
- Janssen Research & Development, LLC$7K
- plus $4K from 3 others
Across 24 payments — averaging $14,440 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$170K
- Takeda Pharmaceuticals U.S.A., Inc.$114K
- AbbVie$63K
What the payments were for
- Consulting fees$45,40174%
- Speaking & faculty fees$12,87521%
- Travel & lodging$2,5914%
- Food & beverage$6851%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 16 | $19,169 |
| GSK | 2 | $8,750 |
| Sanofi Pasteur Inc. | 8 | $8,395 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $7,339 |
| Pfizer | 2 | $7,125 |
| Janssen Research & Development, LLC | 3 | $6,992 |
| AstraZeneca | 2 | $3,007 |
| Inova Diagnostics, Inc. | 1 | $750 |
| Aimmune Therapeutics, Inc. | 2 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REBYOTA$10,688
- C DIFFICILE$7,500
- Entyvio$5,000
- NO PRODUCT DISCUSSED$741
How this compares
$61,658 in reported general payments places this provider in the 90th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide ErBudesonide | 18 | $17,187 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 19 | $1,376 |
| Omeprazole | 18 | $507 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.